Daily Stock Analysis, AVXS, AveXis Inc, priceseries

AveXis Inc. Daily Stock Analysis
Stock Information
Open
83.44
Close
83.09
High
83.88
Low
82.75
Previous Close
83.13
Daily Price Gain
-0.04
YTD High
85.98
YTD High Date
Mar 17, 2017
YTD Low
46.41
YTD Low Date
Jan 3, 2017
YTD Price Change
35.83
YTD Gain
75.81%
52 Week High
85.98
52 Week High Date
Mar 17, 2017
52 Week Low
31.55
52 Week Low Date
Aug 12, 2016
52 Week Price Change
42.87
52 Week Gain
106.59%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 13. 2016
35.96
Sep 26. 2016
40.05
9 Trading Days
11.40%
Link
LONG
Oct 3. 2016
42.00
Oct 18. 2016
46.46
11 Trading Days
10.63%
Link
LONG
Oct 31. 2016
47.50
Nov 17. 2016
63.90
13 Trading Days
34.54%
Link
LONG
Feb 27. 2017
58.07
Mar 21. 2017
73.01
16 Trading Days
25.74%
Link
LONG
Apr 17. 2017
73.18
May 8. 2017
77.66
15 Trading Days
6.13%
Link
Company Information
Stock Symbol
AVXS
Exchange
NasdaqGS
Company URL
http://http://www.avexis.com
Company Phone
972-725-7797
CEO
Sean P. Nolan
Headquarters
Illinois
Business Address
2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN, IL 60015
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001652923
About

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases.

Description

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.